Portal de investigación
Exploration of SUMO2/3 Expression Levels and Autophagy Process in Fragile X-Associated Tremor/Ataxia Syndrome: Addressing Study Limitations and Insights for Future Research.
Fecha de publicación:
Autores de CIPF
Participantes ajenos a CIPF
- Alvarez-Mora MI
- Garrabou G
- Molina-Porcel L
- Grillo-Risco R
- Barcos T
- Cantó-Santos J
- Rodriguez-Revenga L
Grupos de Investigación
Abstract
Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder that appears in adult FMR1 premutation carriers. The neuropathological hallmark of FXTAS is an intranuclear inclusion in neurons and astrocytes. Nearly 200 different proteins have been identified in FXTAS inclusions, being the small ubiquitin-related modifier 2 (SUMO2), ubiquitin and p62 the most highly abundant. These proteins are components of the protein degradation machinery. This study aimed to characterize SUMO2/3 expression levels and autophagy process in human postmortem brain samples and skin fibroblast cultures from FXTAS patients. Results revealed that FXTAS postmortem brain samples are positive for SUMO2/3 conjugates and supported the idea that SUMO2/3 accumulation is involved in inclusion formation. Insights from RNA-sequencing data indicated that SUMOylation processes are significantly upregulated in FXTAS samples. In addition, the analysis of the autophagy flux showed the accumulation of p62 protein levels and autophagosomes in skin fibroblasts from FXTAS patients. Similarly, gene set analysis evidenced a significant downregulation in gene ontology terms related to autophagy in FXTAS samples. Overall, this study provides new evidence supporting the role of SUMOylation and autophagic processes in the pathogenic mechanisms underlying FXTAS.
Datos de la publicación
- ISSN/ISSNe:
- 2073-4409, 2073-4409
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 37830578
Cells MDPI
Documentos
- No hay documentos
Filiaciones
Keywords
- FMR1 premutation, FXTAS, SUMO2/3, SUMOylation, autophagy, p62
Proyectos asociados
PID10470. No se ingresará dinero en el CIPF. La ayuda consiste en un estudio genómico (long & read-sequencing) para 25 muestras.
Investigador Principal: CARMEN ESPINÓS ARMERO
EASI- Genomics . 2020
New players in human BAT differentiation and activation
Investigador Principal: STEFANIA CAROBBIO
COMMISSION OF EUROPEAN COMMUNITIES . 2021
Nanoplataforma Polipeptídica Multimodal de Precisión para el Tratamiento y Monitorización de Tumores Metastásicos. Colab I-36, I-12, I-63, servicio citómica, uji y gva (Esther Roselló)
Investigador Principal: MARIA JESUS VICENT DOCON
CONSELLERIA DE EDUCACION . 2022
ESTUDIO DE LAS DIFERENCIAS DE SEXO EN ENFERMEDADES NEURODEGENERATIVAS CON ABORDAJES
Investigador Principal: FRANCISCO GARCÍA GARCÍA
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2022
THE FUTURE OF BIOMEDICAL RESEARCH (FBR) CIPF LECTURE SERIES
Investigador Principal: FRANCISCO GARCÍA GARCÍA
2023